Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Yasir Y, Elamin"'
Autor:
Charles Lu, Mehmet Altan, Apar Pataer, Tina Cascone, Annikka Weissferdt, Jianjun Zhang, Boris Sepesi, Ara A Vaporciyan, Marcelo V Negrao, Hai T Tran, Stephen G Swisher, John V Heymach, Don L Gibbons, Brett W Carter, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Wayne L Hofstetter, J Jack Lee, Bonnie S Glisson, Myrna C B Godoy, Garrett L Walsh, Jia Wu, Humam Kadara, George R Blumenschein, Heather Y Lin, Nicolas Zhou, William N William, Cheuk H Leung, Frank V Fossella, Anne S Tsao, Jonathan M Kurie, Lauren A Byers, Reza J Mehran, David C Rice, Luisa M Solis Soto
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the efficacy of ne
Externí odkaz:
https://doaj.org/article/6cabe896ecc5458b81684d743e2ba8f9
Autor:
Sheeba J. Sujit, Muhammad Aminu, Tatiana V. Karpinets, Pingjun Chen, Maliazurina B. Saad, Morteza Salehjahromi, John D. Boom, Mohamed Qayati, James M. George, Haley Allen, Mara B. Antonoff, Lingzhi Hong, Xin Hu, Simon Heeke, Hai T. Tran, Xiuning Le, Yasir Y. Elamin, Mehmet Altan, Natalie I. Vokes, Ajay Sheshadri, Julie Lin, Jianhua Zhang, Yang Lu, Carmen Behrens, Myrna C. B. Godoy, Carol C. Wu, Joe Y. Chang, Caroline Chung, David A. Jaffray, Ignacio I. Wistuba, J. Jack Lee, Ara A. Vaporciyan, Don L. Gibbons, John Heymach, Jianjun Zhang, Tina Cascone, Jia Wu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), the independent contribution of quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains underexplor
Externí odkaz:
https://doaj.org/article/8ee2d864530b4ff5bcd6763fb81cd4af
Autor:
Lingzhi Hong, Muhammad Aminu, Shenduo Li, Xuetao Lu, Milena Petranovic, Maliazurina B. Saad, Pingjun Chen, Kang Qin, Susan Varghese, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Amy Spelman, Yasir Y. Elamin, Marcelo V. Negrao, Ferdinandos Skoulidis, Carl M. Gay, Tina Cascone, Saumil J. Gandhi, Steven H. Lin, Percy P. Lee, Brett W. Carter, Carol C. Wu, Mara B. Antonoff, Boris Sepesi, Jeff Lewis, Don L. Gibbons, Ara A. Vaporciyan, Xiuning Le, J. Jack Lee, Sinchita Roy-Chowdhuri, Mark J. Routbort, Justin F. Gainor, John V. Heymach, Yanyan Lou, Jia Wu, Jianjun Zhang, Natalie I. Vokes
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Immune checkpoint inhibitors with or without chemotherapy are now standard of care for non-small cell lung cancer. However, the benefits of combination vs sequential therapy have not been fully explored. Here, the authors analysed 1,133 patient recor
Externí odkaz:
https://doaj.org/article/8e4eb1b2cf4847c68859d771395453bd
Autor:
Kaiwen Wang, PharmD, Robyn Du, BS, Sinchita Roy-Chowdhuri, MD, Ziping T. Li, MD, Lingzhi Hong, MD, Natalie Vokes, MD, Yasir Y. Elamin, MD, Celyne Bueno Hume, MD, Ferdinandos Skoulidis, MD, PhD, Carl M. Gay, MD, PhD, George Blumenschein, MD, Frank V. Fossella, MD, Anne Tsao, MD, Jianjun Zhang, MD, PhD, Niki Karachaliou, MD, Aurora O’Brate, PhD, Claudia-Nanette Gann, MD, Jeff Lewis, MS, Waree Rinsurongkawong, PhD, J. Jack Lee, PhD, MS, DDS, Don Lynn Gibbons, MD, PhD, Ara A. Vaporciyan, MD, John V. Heymach, MD, PhD, Mehmet Altan, MD, Xiuning Le, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100533- (2023)
Introduction: MET amplification is a known resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant NSCLC. Dual EGFR-MET inhibition has been reported with success in overcoming such resistance and inducing clinical benefi
Externí odkaz:
https://doaj.org/article/abe6440483814bd08d4c9b73ab459684
Autor:
Jing Li, Yan Wang, Chad Tang, James Welsh, Renata Ferrarotto, Mehmet Altan, Tina Cascone, Juhee Song, Marcelo V Negrao, John V Heymach, Brett W Carter, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Caroline Chung, George R Blumenschein, Nandita Guha-Thakurta, Jeffrey S Wefel, Amol J Ghia, Debra N Yeboa, Mary Frances McAleer, Kristina D Woodhouse, Susan L McGovern, Chenyang Wang, Betty Y S Kim, Jeffrey S Weinberg, Tina M Briere
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Up to 20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), for which the current standard of care is radiation therapy with or without surgery. There are no prospective data on the safety of stereotactic r
Externí odkaz:
https://doaj.org/article/51e050d61d114362ab9f5637b2331ad5
Autor:
Maliazurina B Saad, PhD, Lingzhi Hong, MD, Muhammad Aminu, MD, Natalie I Vokes, MD, Pingjun Chen, PhD, Morteza Salehjahromi, PhD, Kang Qin, MD, Sheeba J Sujit, PhD, Xuetao Lu, PhD, Elliana Young, MS, Qasem Al-Tashi, PhD, Rizwan Qureshi, PhD, Carol C Wu, ProfMD, Brett W Carter, ProfMD, Steven H Lin, ProfMD, Percy P Lee, ProfMD, Saumil Gandhi, MD, Joe Y Chang, ProfMD, Ruijiang Li, PhD, Michael F Gensheimer, MD, Heather A Wakelee, ProfMD, Joel W Neal, MD, Hyun-Sung Lee, MD, Chao Cheng, PhD, Vamsidhar Velcheti, ProfMD, Yanyan Lou, MD, Milena Petranovic, MD, Waree Rinsurongkawong, PhD, Xiuning Le, MD, Vadeerat Rinsurongkawong, PhD, Amy Spelman, PhD, Yasir Y Elamin, MD, Marcelo V Negrao, MD, Ferdinandos Skoulidis, MD, Carl M Gay, MD, Tina Cascone, MD, Mara B Antonoff, MD, Boris Sepesi, MD, Jeff Lewis, BS, Ignacio I Wistuba, ProfMD, John D Hazle, ProfPhD, Caroline Chung, MD, David Jaffray, ProfPhD, Don L Gibbons, ProfMD, Ara Vaporciyan, ProfMD, J Jack Lee, ProfPhD, John V Heymach, ProfMD, Jianjun Zhang, MD, Jia Wu, PhD
Publikováno v:
The Lancet: Digital Health, Vol 5, Iss 7, Pp e404-e420 (2023)
Summary: Background: Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availabil
Externí odkaz:
https://doaj.org/article/0a63dfd25a6f4694ab5c9c636dd7ce6b
Autor:
Jianhua Zhang, Hao Xu, Alexandre Reuben, Brian Alexander, Jack Lee, Tina Cascone, Jianjun Zhang, Kyle G Mitchell, Marcelo V Negrao, Stephen G Swisher, John V Heymach, Don L Gibbons, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Anne Tsao, Chang-Jiun Wu, Vincent A Miller, Bonnie S Glisson, Karthikeyan Murugesan, Meagan Montesion, Garrett Frampton, Katja Schulze, Ilze Bara, Vincent Shen, Sylvia Hu, Dawen Sui, Michael E Goldberg, David S Barreto, Jacqulyne P Robichaux, Carl M Gay, Lingzhi Hong, Waree Rinsurongkawong, Vassiliki Papadimitrakopoulou, Gaurav Singal, Lee A Albacker, David Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. W
Externí odkaz:
https://doaj.org/article/deb634044c5641f5a4d7746a8b39b598
Autor:
Tina Cascone, Cheuk H. Leung, Annikka Weissferdt, Apar Pataer, Brett W. Carter, Myrna C. B. Godoy, Hope Feldman, William N. William, Yuanxin Xi, Sreyashi Basu, Jing Jing Sun, Shalini S. Yadav, Frank R. Rojas Alvarez, Younghee Lee, Aditya K. Mishra, Lili Chen, Monika Pradhan, Haiping Guo, Ansam Sinjab, Nicolas Zhou, Marcelo V. Negrao, Xiuning Le, Carl M. Gay, Anne S. Tsao, Lauren Averett Byers, Mehmet Altan, Bonnie S. Glisson, Frank V. Fossella, Yasir Y. Elamin, George Blumenschein, Jianjun Zhang, Ferdinandos Skoulidis, Jia Wu, Reza J. Mehran, David C. Rice, Garrett L. Walsh, Wayne L. Hofstetter, Ravi Rajaram, Mara B. Antonoff, Junya Fujimoto, Luisa M. Solis, Edwin R. Parra, Cara Haymaker, Ignacio I. Wistuba, Stephen G. Swisher, Ara A. Vaporciyan, Heather Y. Lin, Jing Wang, Don L. Gibbons, J. Jack Lee, Nadim J. Ajami, Jennifer A. Wargo, James P. Allison, Padmanee Sharma, Humam Kadara, John V. Heymach, Boris Sepesi
Publikováno v:
Nature Medicine. 29:593-604
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvant N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc4d46457c34ffd4bc56a0716fe62bc7
https://doi.org/10.1038/s41591-022-02189-0
https://doi.org/10.1038/s41591-022-02189-0
Autor:
Sonia A. Patel, Monique B. Nilsson, Yan Yang, Xiuning Le, Hai T. Tran, Yasir Y. Elamin, Xiaoxing Yu, Fahao Zhang, Alissa Poteete, Xiaoyang Ren, Li Shen, Jing Wang, Seyed Javad Moghaddam, Tina Cascone, Michael Curran, Don L. Gibbons, John V. Heymach
Publikováno v:
Clinical Cancer Research. 29:1292-1304
Purpose: Patients with advanced non–small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd821c8e27eebd8749bf62deb49ea7dc
https://doi.org/10.1158/1078-0432.ccr-22-3379
https://doi.org/10.1158/1078-0432.ccr-22-3379
Autor:
Jessica Lee, Vivek Subbiah, Shuang Liu, Jason Roszik, David Hong, Funda Meric-Bernstam, John Heymach, Ramona Dadu, Kenneth Hess, Le Huang, Aparna Hegde, Alexander Y Andreev-Drakhlin, Maria Cabanillas, Mimi I Hu, Naifa L Busaidy, Steven I Sherman, Elizabeth G Grubbs, Siraj M Ali, Yasir Y Elamin, George R Simon, George R Blumenschein, Jr, Vassiliki A Papadimitrakopoulou
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
Purpose The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in RET-depe
Externí odkaz:
https://doaj.org/article/c90d0d405f934390885cdc8e42bce7c6